JUSH:CA:CNSX-Jushi Holdings Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.43

Change

-0.01 (-2.27)%

Market Cap

USD 0.08B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

-0.08 (-0.69%)

USD 2.72B
TRUL:CA Trulieve Cannabis Corp

-0.08 (-1.05%)

USD 1.31B
CL:CA Cresco Labs Inc

+0.06 (+4.26%)

USD 0.41B
GRIN:CA Grown Rogue International Inc

-0.02 (-2.15%)

USD 0.20B
PLTH:CA Planet 13 Holdings Inc

-0.01 (-1.82%)

USD 0.17B
AAWH-U:CA Ascend Wellness Holdings Inc.

-0.01 (-2.13%)

USD 0.09B
MRMD:CA MariMed Inc.

-0.04 (-18.99%)

USD 0.07B
AYR-A:CA Ayr Wellness Inc

N/A

USD 0.07B
INNO:CA InnoCan Pharma Corporation

-0.02 (-9.52%)

USD 0.06B
LEEF:CA Leef Brands Inc.

-0.03 (-8.62%)

USD 0.05B

ETFs Containing JUSH:CA

PBI:CA Purpose Best Ideas 3.45 % 0.79 %

+0.03 (+0.07%)

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.44% 32% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.44% 32% F 27% F
Trailing 12 Months  
Capital Gain -44.16% 45% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.16% 45% F 41% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -28.70% 21% F 16% F
Dividend Return -28.70% 21% F 16% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.97% 63% D 53% F
Risk Adjusted Return -70.04% 22% F 17% F
Market Capitalization 0.08B 90% A- 97% N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector